The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma

The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma

Objective: Sarcomas are a group of rare malignancies with various subtypes. Patients with metastatic sarcoma who have failed traditional treatments can possibly achieve better prognoses from using novel therapies, including anti-programmed death-1 (PD-1)-based therapies. Methods: We retrospectively...

Full description

Bibliographic Details
Main Authors:	Jia Lu, Ting Li, Zhichao Liao, Hui Yu, Yongtian Zhao, Haixiao Wu, Zhiwu Ren, Jun Zhao, Ruwei Xing, Sheng Teng, Yun Yang, Xiangchun Li, Kexin Chen, Jonathan Trent, Jilong Yang
Format:	Article
Language:	English
Published:	China Anti-Cancer Association 2022-06-01
Series:	Cancer Biology & Medicine
Subjects:	sarcoma pd-1 pd-l1 immunotherapy angiogenesis safety efficacy biomarker
Online Access:	https://www.cancerbiomed.org/content/19/6/910

Similar Items

Activity of PD-1 Inhibitor Combined With Anti-Angiogenic Therapy in Advanced Sarcoma: A Single-Center Retrospective Analysis
by: Yang You, et al.
Published: (2021-11-01)

PD-1/L1 inhibitor plus chemotherapy in the treatment of sarcomas
by: Zhichao Tian, et al.
Published: (2022-08-01)

The efficacies and biomarker investigations of antiangiogenic agents and PD-1 inhibitors for metastatic soft tissue sarcoma: A multicenter retrospective study
by: Zhiyong Liu, et al.
Published: (2023-02-01)

Long-Term Remission with Ipilimumab/Nivolumab in Two Patients with Different Soft Tissue Sarcoma Subtypes and No PD-L1 Expression
by: Maggie Zhou, et al.
Published: (2021-03-01)

Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas
by: Kazuhiko Hashimoto, et al.
Published: (2021-07-01)

Evaluation of PD-L1 Expression in Undifferentiated Pleomorphic Sarcomas, Liposarcomas and Chondrosarcomas
by: Yifan Zhang, et al.
Published: (2022-02-01)

PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue – prognostic implications and rationale for immunotherapy
by: Melanie Boxberg, et al.
Published: (2018-03-01)

Immunohistochemical expression and clinicopathological assessment of PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in highly aggressive soft tissue sarcomas
by: Kazuhiko Hashimoto, et al.
Published: (2022-04-01)

Kaposi’s Sarcoma-Associated Herpesvirus Increases PD-L1 and Proinflammatory Cytokine Expression in Human Monocytes
by: Kurtis M. Host, et al.
Published: (2017-11-01)

Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies
by: Jihane Boustani, et al.
Published: (2021-09-01)

Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives
by: Yating Zhao, et al.
Published: (2021-07-01)

Sarcoma – correlation between CD73 and PD-L1 and their relationship with prognosis
by: Abdullah Evren Yetişir, et al.
Published: (2023-03-01)

Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review
by: Yiru Zhang, et al.
Published: (2023-01-01)

PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma
by: Sang Kyum Kim, et al.
Published: (2021-03-01)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
by: Yiru Long, et al.
Published: (2022-05-01)

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer
by: Janice M. Mehnert, et al.
Published: (2019-03-01)

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
by: Kazushige Yoshida, et al.
Published: (2020-01-01)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
by: Mengke Niu, et al.
Published: (2021-03-01)

Clinical Research Progress of Anti PD-1/PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
by: Zhiyu HUANG, et al.
Published: (2015-11-01)

Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
by: Liping Pei, et al.
Published: (2023-02-01)

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
by: Dawei Wu, et al.
Published: (2022-02-01)

Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma
by: Sun X, et al.
Published: (2022-09-01)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
by: Yaxiong Zhang, et al.
Published: (2018-12-01)

Case report: Targeting the PD-1 receptor and genetic mutations validated in primary histiocytic sarcoma with hemophagocytic lymphohistiocytosis
by: Yan Zhao, et al.
Published: (2023-03-01)

Global research trends on anti-PD-1/anti-PD-L1 immunotherapy for triple-negative breast cancer: A scientometric analysis
by: Jinyao Wu, et al.
Published: (2023-01-01)

Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
by: Junjie Liu, et al.
Published: (2022-09-01)

Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer
by: Yi Que, et al.
Published: (2021-07-01)

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
by: Ming Yi, et al.
Published: (2022-12-01)

Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
by: Tian Zeng, et al.
Published: (2019-12-01)

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy
by: Kim A. Brogden, et al.
Published: (2018-02-01)

Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis
by: Yuegang Li, et al.
Published: (2022-10-01)

Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers
by: Yuehong Kong, et al.
Published: (2021-03-01)

Research Progress of PD-1/PD-L1 Checkpoint Inhibitors in (Neo) Adjuvant Therapy for Malignant Melanoma
by: ZOU Hanhui, et al.
Published: (2020-02-01)

نقش PD-1/ PD-L1 و Anti-PD-1/ PD-L1 در پیشرفت و سرکوب سرطان
by: نرگس عبدالهی, et al.
Published: (2023-11-01)

The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
by: Lihu Gu, et al.
Published: (2019-06-01)

Epithelioid granulomatous lesions express abundant programmed death ligand-1 (PD-L1): a discussion of adverse events in anti-PD-1 antibody-based cancer immunotherapy
by: Terufumi Kubo, et al.
Published: (2021-07-01)

Clinical benefit of neoadjuvant anti‐PD‐1/PD‐L1 utilization among different tumors
by: Zhiyang Li, et al.
Published: (2021-03-01)

Key differences between anti-PD-1/PD-L1 inhibitors
by: N. V. Zhukova, et al.
Published: (2022-06-01)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
by: Yuanyuan Wang, et al.
Published: (2021-05-01)

PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma
by: Yu-Min Zhong, et al.
Published: (2022-10-01)